Clinical Trials in ALS: What Did We Learn from Recent Trials in Humans?

Publisher： Karger

E-ISSN： 1660-2862|2|3-4|208-214

ISSN： 1660-2854

Source： Neurodegenerative Diseases, Vol.2, Iss.3-4, 2006-01, pp. : 208-214

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The yeast genome project: what did we learn?

By Dujon B.  

Trends in Genetics, Vol. 12, Iss. 7, 1996-07 ,pp. : 263-270

Elsevier

Access to resources Recommend Favorite

How Can We Improve Transfer of Outcomes from Randomized Clinical Trials to Clinical Practice with Disease-Modifying Drugs in Alzheimer's Disease?

By  

Neurodegenerative Diseases, Vol. 13, Iss. 2-3, 2013-08 ,pp. : 197-199

Karger

Access to resources Recommend Favorite

Freshwater ecology and biodiversity in the tropics: what did we learn from 30 years of onchocerciasis control and the associated biomonitoring of West African rivers?: Aquatic Biodiversity (Guest Editor: Koen Martens)

By Lévêque C.   Hougard J. M.   Resh V.   Statzner B.   Yaméogo L.  

Hydrobiologia, Vol. 500, Iss. 1-3, 2003-06 ,pp. : 23-49

Springer Publishing Company

Access to resources Recommend Favorite

Clinical trials with missing data

By Song Juwon  

Biometrics, Vol. 71, Iss. 2, 2015-06 ,pp. : 558-559

Wiley-Blackwell

Access to resources Recommend Favorite

Clinical trials with missing data

By  

BIOMETRICS, Vol. 71, Iss. 2, 2015-06 ,pp. : 558-559

John Wiley & Sons Inc

Access to resources Recommend Favorite